辛伐他汀联合非诺贝特治疗混合性高脂血症的临床观察

Clinical observation of simvastatin combined with fenofibrate in the treatment of mixed hyperlipemia

目的探析辛伐他汀联合非诺贝特治疗混合性高脂血症的临床效果。方法 60例混合性高脂血症患者,按药物治疗不同随机分为B组和A组,各30例。B组给予辛伐他汀进行治疗,A组则在B组患者基础上联合应用非诺贝特进行治疗。对比两组的治疗效果、各项血清指标变化以及不良反应发生情况。结果两组患者应用不同的药物治疗后,临床症状均有所改善,A组患者总有效率为96.67%,明显高于B组的73.33%,差异具有统计学意义(P<0.05)。A组不良反应发生率为6.7%低于B组的26.7%,差异具有统计学意义(P<0.05)。治疗后,A组患者甘油三酯、总胆固醇以及低密度脂蛋白水平分别为(1.78±0.13)、(5.13±0.09)、(2.41±0.24)mmol/L,均低于B组的(3.12±0.78)、(7.01±0.48)、(3.56±0.35)mmol/L,差异均有统计学意义(P<0.05)。结论混合性高脂血症应用辛伐他汀与非诺贝特联合治疗效果较佳,值得在临床中推广应用。

Objective To explore and analyze the clinical effect of simvastatin combined with fenofibrate in the treatment of mixed hyperlipemia. Methods A total of 60 mixed hyperlipemia patients were divided by different drug therapy into group B and group A, with 30 cases in each group. Group B received simvastatin for treatment, and group A received fenofibrate for treatment on the basis of group B. Comparison were made on treatment effect, serum index changes and adverse reactions occurrence in two groups. Results After different drug therapy, both groups had improved clinical symptoms. Group A had obviously higher total effective rate as 96.67% than 73.33% in group B, and the difference had statistical significance (P<0.05). Group A had lower incidence of adverse reactions as 6.7% than 26.7% in group B, and the difference had statistical significance (P<0.05). After treatment, group A had triglyceride, total cholesterol and low density lipoprotein levels respectively as (1.78±0.13) mmol/L, (5.13±0.09) mmol/L, and (2.41±0.24) mmol/L, which were all lower than (3.12±0.78),(7.01±0.48) and (3.56±0.35) mmol/L in group B, and their difference had statistical significance (P<0.05).Conclusion Combination of simvastatin and fenofibrate shows good treatment effect in the treatment of mixed hyperlipemia, and it is worth clinical promotion and application.